Biocon’s Q3 results show strong revenue and profit growth, led by Biosimilars and Generics. Strategic debt reduction and R&D investments position the company for robust FY27 performance.
.jpeg "Thermo Fisher & Datavant Partner to Enhance Clinical Research")
Thermo Fisher partners with Datavant to enhance clinical research by connecting real-world data (RWD) and speeding up evidence generation for biotech and pharma companies.
.png "Novo Nordisk to Broaden Wegovy Access With Vials")
Novo Nordisk is preparing to introduce Wegovy in vial format, expanding delivery options for its blockbuster weight-loss drug as competition intensifies in the fast-growing obesity treatment market.
.png "Eli Lilly Bets Big on Weight-Loss Pill Ahead of FDA")
Eli Lilly and Company has built a $1.5 billion inventory of its experimental weight-loss pill ahead of a key FDA decision. The move signals confidence in approval and a push to avoid supply shortages at launch.
Biological E Limited has received Phase II prequalification from the World Health Organization for its Novel Oral Polio Vaccine type 2, strengthening global supply and boosting efforts to control vaccine-derived polio outbreaks worldwide.
Bharat Biotech is exploring a new biologics manufacturing facility near Chennai, aiming to produce advanced therapies including monoclonal antibodies and diabetes treatments as part of its long-term growth strategy.
Cipla Foundation and IISc have launched a Centre for Pulmonary Medicine in Bengaluru, offering advanced care, research, and training to tackle India’s rising respiratory health challenges.
Dabur India today inaugurated its first south Indian manufacturing plant in Tindivanam, Tamil Nadu. The Rs 400 crore facility will produce popular personal care products and drive local employment.
Sanofi has finalized its acquisition of Dynavax, adding hepatitis B vaccine HEPLISAV-B and a shingles vaccine candidate to its portfolio. The $15.50 per share deal strengthens Sanofi’s position in adult immunization.
USV Pharma is in advanced talks to acquire an 85% stake in Wellbeing Nutrition at a Rs 1,600 crore valuation, marking a major move into India’s fast-growing consumer health and supplements market.
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")